Proteus Digital Health is focused on enabling a new category of therapy: Digital Medicines. These offerings include widely used drugs, formulated so they communicate when they have been swallowed; a wearable patch that detects medicines and captures physiologic response; mobile applications to support patient self-care and physician decision-making; and data analytics to serve the needs of health system managers. The company has more than 440 issued patents that protect this enabling technology, and regulatory clearances in the U.S., European Union and China.
Proteus Digital Health is privately held by investors that include Carlyle, Essex Woodlands, Kaiser Permanente®, Medtronic®, Novartis®, Otsuka®, Oracle®, and ON Semiconductor®. Further information is available at: www.proteus.com
Source: Company Press Release
*Based on Preferred Stock Price, Proteus Digital Health does not have a stock symbol since it is currently private and is yet to have an IPO.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Proteus Digital Health or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.